{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"5.027","upperLimit":"9.758","value":"7.75"},{"groupId":"OG001","lowerLimit":"11.203","upperLimit":"15.211","value":"12.71"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"153"},{"groupId":"OG001","value":"154"}],"units":"Participants"}],"description":"TTP was defined as time from randomization to the date of first documentation of PD, as determined by the IRC. As per IMWG criteria, PD was defined for participants with increase of \\>= 25% from lowest confirmed value in any one of the following criteria: serum M-protein (the absolute increase must be \\>= 0.5 g/dL), serum M-protein increase \\>=1 g/dL if the lowest M component was \\>=5 g/dL; urine M-component (the absolute increase must be \\>=200 mg/24hour), appearance of new lesion(s), \\>=50% increase from nadir in SPD of \\>1 lesion, or \\>=50% increase in the longest diameter of a previous lesion \\>1 centimeter in short axis.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants received pomalidomide 4 mg PO on Days 1 to 21 of each 28-day treatment cycle plus dexamethasone 40 mg (participants \\>= 75 years of age received 20 mg dexamethasone) PO on Days 1, 8, 15 and 22 of each 28-day treatment cycle until disease progression or unacceptable toxicity or participant's wish to discontinue study treatment, or any other reason, whichever comes first (maximum exposure: 73.7 weeks).","id":"OG000","title":"Pd (Pomalidomide + Dexamethasone)"},{"description":"Participants received isatuximab 10 mg/kg IV infusion on Days 1, 8, 15, and 22 at Cycle 1, and then on Days 1 and 15 of subsequent cycles plus pomalidomide 4 mg PO on Days 1 to 21 of each 28-day treatment cycle and dexamethasone 40 mg (participants \\>= 75 years of age received 20 mg dexamethasone), PO or IV on Day 1, 8, 15, 22 of each 28-day treatment cycle until disease progression or unacceptable toxicity or participant's wish to discontinue study treatment, or any other reason, whichever comes first (maximum exposure: 76.7 weeks).","id":"OG001","title":"IPd (Isatuximab + Pomalidomide + Dexamethasone)"}],"paramType":"MEDIAN","populationDescription":"Analysis was performed on ITT population.","reportingStatus":"POSTED","timeFrame":"From the date of randomization to the date of first documentation of progression, or initiation of further anti-myeloma treatment or data cut-off whichever comes first (maximum duration 76.7 weeks)","title":"Time to Progression (TTP) as Per Independent Response Committee","type":"SECONDARY","unitOfMeasure":"months"}